2025
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar A, Selby L, Lustberg M, Pawlik T. Surgical Management of Breast Cancer Liver Metastasis. Hematology/Oncology Clinics Of North America 2025, 39: 25-35. PMID: 39510675, DOI: 10.1016/j.hoc.2024.08.012.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesSystemic chemotherapyHepatic resectionAblation therapyIsolated breast cancer liver metastasesLong-term outcomes of womenProlonged disease-free intervalLocal-regional therapyCancer liver metastasesDisease-free intervalOutcomes of womenBreast cancer metastasisLong-term outcomesRegional therapyLiver metastasesOverall survivalSurgery benefitMultidisciplinary settingCancer metastasisPatientsResectionChemotherapyMetastasisTherapySurgery
2024
Eyebrow and Eyelash Loss in Patients With Cancer.
Rose L, Khuhro A, Minta A, Novice M, Novice T, Lustberg M, Ruddy K, Rake E, Loprinzi C, Dulmage B. Eyebrow and Eyelash Loss in Patients With Cancer. Journal Of Drugs In Dermatology 2024, 23: 327-331. PMID: 38709698, DOI: 10.36849/jdd.8003.Peer-Reviewed Original ResearchConceptsPrevention optionsRadiation therapyTopical vasoconstrictorEndocrine therapyEyelash lossTreatment optionsPrescription medicationsCancer treatmentPatientsScalp coolingHair lossRobust researchMadarosisPermanent tattoosTherapyCancerTreatmentEyebrowsEyelash hairScalpOptionsChemotherapyCryotherapyVasoconstrictorDermatologistsFeasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapy
2023
P13-029-23 Cross-Sectional Associations of Serum Fatty Acids and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy
Melink Z, Schnell P, Ormiston K, Weinhold K, Kopec R, Lustberg M, Orchard T. P13-029-23 Cross-Sectional Associations of Serum Fatty Acids and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy. Current Developments In Nutrition 2023, 7: 100485. DOI: 10.1016/j.cdnut.2023.100485.Peer-Reviewed Original ResearchMitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Lustberg M, Kuderer N, Desai A, Bergerot C, Lyman G. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology 2023, 20: 527-542. PMID: 37231127, PMCID: PMC10211308, DOI: 10.1038/s41571-023-00776-9.Peer-Reviewed Original ResearchConceptsAdverse eventsEvidence-based clinical practice guidelinesChemotherapy-associated adverse eventsNon-pharmacological treatment strategiesAdverse effectsClinical practice guidelinesAdverse treatment effectsCourse of therapyTotality of evidenceQuality of lifeTerms of survivalRisk assessment toolOptimal therapyCancer survivorsRisk factorsOncology practiceTreatment strategiesPractice guidelinesUnderlying biological mechanismsAppropriate managementAnticancer treatmentCancer treatmentEffective interventionsTreatment effectsChemotherapyHair loss during and after breast cancer therapy
Rose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.Peer-Reviewed Original ResearchConceptsTreatment optionsHair lossDistressing side effectsChemotherapy-induced alopeciaCancer therapyBreast cancer therapyEndocrine therapyMajor surgeryPatient counselingTelogen effluviumBreast cancerBreast oncologistsSide effectsPrevention strategiesAlopeciaTherapyChemotherapyPatientsSurgeryOncologistsOptionsEtiologyCancer
2022
Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Lockwood B, El-Jawahri A, Walker A, Ehrman S, Russell D, Kale S, Gustin J, Bose-Brill S, LeBlanc T, Luger S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal Of Adolescent And Young Adult Oncology 2022, 12: 592-598. PMID: 36367711, DOI: 10.1089/jayao.2022.0082.Peer-Reviewed Original ResearchConceptsYoung adultsHigh-risk AMLUnpredictable illness trajectoriesPatient-reported outcomesHospitalized young adultsHighest post-traumatic stress disorderPost-traumatic stress disorderInduction chemotherapyIntensive chemotherapyUnmet psychological needsClinical trialsIllness trajectoryWeek 2Secondary analysisStress disorderOlder adultsPsychological distressLife disruptionChemotherapyWorse qualityAdultsAMLHigh anxietyAnxietyHospitalizationThe Association of Serum Inflammatory Markers and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy
Zhang Z, Schnell P, Ormiston K, Weinhold K, Kopec R, Lustberg M, Orchard T. The Association of Serum Inflammatory Markers and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy. Current Developments In Nutrition 2022, 6: 6009258. PMCID: PMC9193788, DOI: 10.1093/cdn/nzac052.025.Peer-Reviewed Original ResearchSerum inflammatory markersInflammatory markersSelf-reported cognitive functionBreast cancerIL-1βTNF-RIICognitive functionIL-8Lower serum IL-1βHigher tumor necrosis factorHigher interleukin-8Lower interleukin-1βSerum omega-3Serum IL-1βLower IL-1βTumor necrosis factorEnzyme-linked immunoassayAdjuvant chemotherapyInterleukin-1βInterleukin-6Cognitive dysfunctionInterleukin-8Necrosis factorQuestionnaire scoresChemotherapyThe Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients
Bennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients. Current Developments In Nutrition 2022, 6: 6009237. PMCID: PMC9193887, DOI: 10.1093/cdn/nzac052.004.Peer-Reviewed Original ResearchPlasma concentrationsCognitive impairmentLong-term cognitive impairmentNutritional targetsDocosahexaenoic acidNervonic acidEicosapentaenoic acidOmega-3 fatty acidsNeo-adjuvant chemotherapyBreast cancer patientsEffect of chemotherapyBreast cancer chemotherapyFatty acidsBreast cancer treatmentHippocampal concentrationsDietary interventionSolid tumor treatmentCancer patientsChemotherapy treatmentFatty acid concentrationsObjective biomarkersBreast cancerImpact of visitsChemotherapyMead acid
2021
Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing Chemotherapy
Zhang Z, Ormiston K, Weinhold K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing Chemotherapy. Journal Of The Academy Of Nutrition And Dietetics 2021, 121: a18. DOI: 10.1016/j.jand.2021.06.034.Peer-Reviewed Original ResearchThe Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients
Bennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients. Current Developments In Nutrition 2021, 5: 70. PMCID: PMC8180829, DOI: 10.1093/cdn/nzab034_004.Peer-Reviewed Original ResearchFat-soluble vitaminsNSAID useMultivitamin useNon-steroidal anti-inflammatory drug useAnti-inflammatory drug useNeo-adjuvant chemotherapyBreast cancer patientsPro-inflammatory cytokinesEffect of chemotherapyFat-soluble vitamin concentrationsBreast cancer chemotherapyMethods Serum samplesFree-living patientsChemotherapy commencementSerum luteinSerum retinolCancer patientsSerum concentrationsChemotherapy treatmentInflammatory processBreast cancerMerit further investigationChemotherapyPlasma carotenoidsDrug useReal-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States.
Williams N, Paxman R, Thornhill E, Kassem M, Grimm M, Dulmage B, Cathcart-Rake E, Ruddy K, Pariser A, Gatti-Mays M, Cherian M, VanDeusen J, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Loprinzi C, Lustberg M. Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. Journal Of Clinical Oncology 2021, 39: e18739-e18739. DOI: 10.1200/jco.2021.39.15_suppl.e18739.Peer-Reviewed Original ResearchScalp coolingNational Comprehensive Cancer NetworkMedical Oncology guidelinesComprehensive Cancer NetworkMajority of patientsOncology guidelinesCategory 2ABreast cancerHair lossCancer NetworkSide effectsChemotherapyLargest reportPatientsReal-world useOlder adultsScalpEuropean SocietyFurther studiesAlopeciaCancerDescriptive statisticsGenitourinaryLungGynecology
2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapy
2018
Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based Chemotherapy
Orchard T, Gaudier-Diaz M, Phuwamongkolwiwat-Chu P, Andridge R, Lustberg M, Bomser J, Cole R, Belury M, DeVries A. Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based Chemotherapy. Nutrients 2018, 10: 2004. PMID: 30567351, PMCID: PMC6316589, DOI: 10.3390/nu10122004.Peer-Reviewed Original ResearchConceptsDHA dietSynaptic damageSecond injectionPro-inflammatory cytokines IL-1βChemotherapy-treated miceKC/GROCytokines IL-1βLong-term brainLow-sucrose dietTwo-injection regimenQuality of lifeSpecific brain regionsBrain DHARegion-specific effectsC57BL/6 miceCancer survivorsFunction markersIL-1βIL-6Synaptic markersIL-5Mouse modelNeuroinflammationSucrose dietChemotherapy
2017
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski R, Duggan M, Stiff A, Markowitz J, Trikha P, Levine K, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Reinbolt R, Mrozek E, Byrd J, Caligiuri M, Mace T, Carson W. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy 2017, 66: 1437-1447. PMID: 28688082, PMCID: PMC5647220, DOI: 10.1007/s00262-017-2038-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBlack or African AmericanBreast NeoplasmsCell CountChemotherapy, AdjuvantCyclophosphamideCytokinesDoxorubicinFemaleGranulocytesHumansMiddle AgedMonocytesMyeloid-Derived Suppressor CellsNeoadjuvant TherapyPaclitaxelPilot ProjectsTreatment OutcomeWhite PeopleConceptsMyeloid-derived suppressor cellsPathologic complete responseG-MDSC levelsNeo-adjuvant chemotherapyG-MDSCSuppressor cellsComplete responseAnti-HER2 therapyPeripheral blood levelsBreast cancer patientsAfrican American patientsBreast cancer typesCyclophosphamide therapyBlood levelsCancer patientsLast administrationAmerican patientsBreast cancerPatientsFlow cytometryCancer typesChemotherapySignificant riseConfidence intervalsCycle 1
2016
Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients.
Monfort S, Pan X, Patrick R, Singaravelu J, Layman R, Mrozek E, Ramaswamy B, Reinbolt R, Wesolowski R, Naughton M, Shapiro C, Loprinzi C, Chaudhari A, Lustberg M. Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients. Journal Of Clinical Oncology 2016, 34: 10098-10098. DOI: 10.1200/jco.2016.34.15_suppl.10098.Peer-Reviewed Original Research
2013
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy
Wenzell C, Berger M, Blazer M, Crawford B, Griffith N, Wesolowski R, Lustberg M, Phillips G, Ramaswamy B, Mrozek E, Flynn J, Shapiro C, Layman R. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care In Cancer 2013, 21: 2845-2851. PMID: 23748485, PMCID: PMC3769492, DOI: 10.1007/s00520-013-1865-9.Peer-Reviewed Original ResearchConceptsDay 1Emetogenic chemotherapyCR rateDay 2Doxorubicin/cyclophosphamide chemotherapyPilot studyOverall complete responseSame patient populationAntiemetic regimenAntiemetic regimensPAD armCyclophosphamide chemotherapyPrimary endpointFeared complicationComplete responseProspective studyPatient populationResultsA totalBreast cancerPatientsRegimensChemotherapyOverall CROndansetronDescriptive statistics
2011
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.Peer-Reviewed Original ResearchConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyHypersensitivity reactionsRescue medicationPaclitaxel dosesSecond doseDoses of paclitaxelBreast cancer patientsUse of paclitaxelPotential unwanted side effectsConclusionsIn patientsPrimary endpointSubsequent dosesUnwanted side effectsCancer patientsPremedicationSide effectsPatientsSolid tumorsDoses 3MedicationsChemotherapyDosesHypersensitivityDose
2010
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).
Mrozek E, Lustberg M, Knopp M, Spigos D, Yang X, Houton L, Ramaswamy B, Layman R, Povoski S, Agnese D. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Journal Of Clinical Oncology 2010, 28: 604-604. DOI: 10.1200/jco.2010.28.15_suppl.604.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBreast cancerDynamic contrast magnetic resonance imagingWeekly nanoparticle albumin-bound paclitaxelNanoparticle albumin-bound paclitaxelClinical stage IIPhase II trialAlbumin-bound paclitaxelContrast magnetic resonance imagingMagnetic resonance imagingII trialResonance imagingStage IIBevacizumabCarboplatinChemotherapyCancerPaclitaxelTrials